- LOGIN
- MemberShip
- 2025-12-23 06:57:22
- Company
- Intensifying competition in ulcerative colitis drug market
- by Son, Hyung-Min Mar 04, 2024 05:53am
- New drug development for conquering ulcerative colitis drives competition among global pharmaceutical companies. Competition in the market will likely intensify due to the efficacy shown by new drugs, including JAK inhibitors Rinvoq and Xeljanz, anti-integrin drugs, and S1P receptor modulators, in clinical trials, in addition to biological medicine Omvoh, a recently approved drug. While TNF-alpha inhibitors such as Humira and Remicade currently dominate the market for ulcerative colitis, the market landscape is forecasted to change. Omvoh, Eli Lily’s interleukin (IL)-23 inhibitor, has been approved in Korea, the industry said on the 27th. Omvoh can treat patients with ulcerative colitis who have previously had failed response to corticosteroids or immunomodulators. Omvoh selectively binds to the p19 subunit of IL-23 and offers a targeted treatment mechanism for the disease. The efficacy of Omvoh was confirmed in Phase 3 LUCENT-1 and 2 clinical trials that included patients with moderately active ulcerative colitis. The clinical trials enrolled patients who had inadequate response to corticosteroids, immunomodulators, or one or more biological medicines. The patients were randomized to receive Omvoh or placebo, starting with a 12-week intravenous administration followed by a 40-week maintenance therapy through subcutaneous injection. The clinical results have shown that the Omvoh group demonstrated a clinical remission rate of 24.2% compared to 13.3% in the placebo group. The Omvoh group achieved 27.1% in histologic-endoscopic mucosal improvement (HEMI), a significant improvement compared to 13.9% in the placebo group. Based on the results after evaluating 544 patients who underwent a 40-week maintenance therapy, 49.9% of patients in the Omvoh group achieved clinical remission, compared to 25.1% of the placebo group, demonstrating Omvoh’s efficacy. Regarding the safety of Omvoh, the most common adverse reactions associated with Omvoh were respiratory infections (7.9%), headaches (3.3%), and rash (1.1%). Omvoh will likely compete with Janssen’s Stelara, an IL-12 and IL-23 inhibitor. Stelara is indicated for Crohn’s disease, besides ulcerative colitis. Eli Lily, the company responsible for developing Omvoh, is currently evaluating Omvoh for Crohn’s disease in clinical trials. Skyrizi, an interleukin-23(IL-23) inhibitor.In addition to Omvoh, the company is also working on securing indications of interleukin inhibitors for treating ulcerative colitis. Abbvie is also developing Skyrizi, an interleukin-23(IL-23) inhibitor like Omvoh, for the treatment of ulcerative colitis. Skyrizi received approval in Korea only for Crohn’s disease. Both the INSPIRE study, which evaluated the effectiveness of induction therapy at 12 weeks, and the Phase 3 COMMAND clinical study, which evaluated maintenance therapy at 52 weeks, demonstrated Skyrizi’s effectiveness compared to the placebo group. Janssen is developing Tremfya, an IL-23 inhibitor, for the treatment of ulcerative colitis. In the Phase 2 clinical study, Tremfya’s clinical response was achieved in 80% of Tremfya-treated patients. Janssen is conducting a multinational Phase 3 clinical study in patients with active ulcerative colitis. S1P receptor modulators have also proven effective, in addition to JAK inhibitors and anti-integrin drugs In addition to interleukin inhibitors, JAK inhibitors, and anti-integrin drugs have secured indications for ulcerative colitis. JAK inhibitors work by blocking the activity of JAK, a kinase that regulates immunity and inflammation. This mechanism of action is effective in reducing inflammation. JAK inhibitors are used to treat autoimmune diseases such as ulcerative colitis, rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease. Eisai’s Jyseleca, Pfizer’s Xeljanz, and Abbvie’s Rinvoq. Among the JAK inhibitors that have received approval in Korea, the medicines that have secured indications for ulcerative colitis are Abbvie’s Rinvoq, Eisai’s Jyseleca, and Pfizer’s Xeljanz. These drugs are undergoing clinical trials to evaluate their effectiveness as maintenance therapy for ulcerative colitis. Takeda’s Kynteles, an anti-integrin drug, has secured an indication for ulcerative colitis. Kynteles inhibits the migration of lymphocytes, which causes inflammation, into the gastrointestinal tract. Recently, the sphingosine-1-phosphate (S1P) receptor modulator has entered the market. Pfizer’s Velsipity recently received approval in Europe after securing approval in the United States last year. Inhibition of the S1P receptor can reduce the leakage of lymphocytes circulating in the lymph nodes, thereby diminishing inflammatory responses. Velsipity demonstrated efficacy in patients with ulcerative colitis who have previously had a failed response or intolerance to one or more treatments. Velsipity has shown effectiveness in patients who have had an inadequate response to at least one or more biologic or Janus kinase JAK inhibitor therapy compared to the placebo. It has been shown that there are improvements in endoscopic outcomes, alleviation of symptoms, and a restoration of the intestinal barrier. Velsipity aims to compete with BMS’s similar S1P receptor modulator, Zeposia. Zeposia, which received approval in Korea last year, secured reimbursement this year and launched in the market. It has landed in general hospitals, where prescriptions are being actively written.
- Company
- Generics of ‘Opsumit’ face tough competition in KOR
- by Kim, Jin-Gu Mar 04, 2024 05:52am
- The product photos of Opsumit (left) and Masiten (right). In the market for the treatment of pulmonary arterial hypertension (PAH) with the active ingredient macitentan, the period of priority of sale given to the first generic drugs is set to expire on the first of next month. While Janssen’s ‘Opsumit’ competes with Samjin Pharm’s ‘Masiten’ in the market, Daewoong Pharmaceutical’s newly launched ‘Macimit’ is expected to join the competition. As the generic’s market share is insignificant at below 1%, Daewoong’s introduction into the market draws the pharmaceutical industry’s attention related to potential market expansion in the treatment of pulmonary arterial hypertension (PAH) with the active ingredient macitentan. The sales of Opsumit 13%↓ in a year due to drug pricing decreases following the generic launch. The market size for the treatment of pulmonary arterial hypertension (PAH) with the active ingredient macitentan totaled 15.2 billion won last year, according to a pharmaceutical market research company IQVIA on the 29th. This figure represents a 13% decrease from 17.4 billion won in 2022. The market has gradually expanded, with 11.9 billion won in 2019, 16.3 billion won in 202, 16.0 billion won in 2021, and 17.4 billion won in 2022. However, the sales decreased by over 10% last year. The decrease in sales is likely due to the drug pricing decrease of the original medicine following the generic launch. Samjin Pharm filed a claim for passive trials to confirm the scope of a right involving the active ingredient patent of Opsumit against Janssen in May 2022. Samjin Pharm won the first trial in April of the following year. Last May, Samjin Pharm launched Masiten Tab after receiving the trial results. During the same period, the price of Opsumit, Janssen’s original medicine, decreased by 30%. The Ministry of Health and Welfare (MOHW) issued a decrease in Opsumit price following the reimbursement listing of the drugs with the same active ingredient. Janssen has appealed to the patent court in response to the first trial judgement. However, the company did not file a suspension of execution related to the drug pricing reduction. While accepting the government’s measure of drug pricing reduction, Janssen has decided to continue with the patent dispute with Samjin Pharm to protect the patent right. The quarterly sales of the treatments Opsumit, the original drug for treating pulmonary arterial hypertension (PAH) with the active ingredient macitentan, and its generic, Masiten. The quarterly sales of Opsumit steadily recorded 4.0 to 4.6 billion won until the second quarter of last year, then rapidly dropped to around 3 billion won after the third quarter. The decrease is due to a reduction in drug pricing that took effect after the third quarter of last year, following the generic launch in May of last year. Masiten had a market share of 0.5% in Q4 last year. Will Daewoong’s introduction lead to an expansion of the generics market? Samjin received a right for priority of sale after successfully challenging the Opsumit patent. Daewoong also challenged the same patent for Opsumit, but Samjin was a step ahead in obtaining the approval for its generic version. Therefore, Samjin obtained the priority of sale for the Opsumit generic alone. The priority of sale was granted from April 21st of last year until March 1st of this year. Although Samjin sold the generic without competition, Masiten’s impact on the market is insignificant. Last year, Masiten generated cumulative sales of merely over 20 million won. After the priority of sale ends, another generic is expected to enter the market on the 1st of next month. Daewoong Pharmaceutical obtained approval for their Macimit, as a generic version of Opsumit, in May of last year. It is anticipated that Daewoong Pharmaceutical will launch the product after next month. Daewoong’s introduction draws the pharmaceutical industry’s attention regarding the potential market expansion of generics containing the active ingredient macitentan. In the market of the treatment of pulmonary arterial hypertension (PAH) with the active ingredient macitentan, Masiten had a market share of 0.5% in the fourth quarter of last year.
- Company
- Bayer releases 2 new CVD drugs with reimb in KOR
- by Eo, Yun-Ho Mar 04, 2024 05:52am
- Bayer Korea, which has been slow to launch new drugs, is making a comeback, recently succeeding in reimbursing two of its cardiovascular drugs in Korea. According to industry sources, Bayer Korea launched its heart failure drug ‘Verquvo (vericiguat)’ with reimbursement on September 1 last year and its kidney disease drug ‘Kerendia (finerenone)’ on February 1 this year. The addition of the two drugs is expected to revitalize Bayer's cardiovascular division, which did not have a prominent pipeline since the launch of its novel oral anticoagulant (NOAC) ‘Xarelto (rivaroxaban).’ Verquvo, the first sGC stimulator for heart failure Verquvo was approved in December 2021 as a combination therapy in Korea as a treatment to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient intravenous (iv) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. Conventional heart failure treatments work by blocking the harmful effects of the natural neurohormonal system that is activated by myocardial and vascular dysfunction. In contrast, Verquvo is a soluble sGC stimulator that has a novel mechanism of action to improve myocardial and vascular function by catalyzing the synthesis of intracellular cyclic guanosine monophosphate (cGMP), which regulates cardiac contractility, vascular tone, and cardiac remodeling. It is the first-in-class sGC stimulator approved for the treatment of chronic heart failure. The Phase III VICTORIA trial, which became the basis for Verquvo’s approval, was shown to reduce the risk of hospitalization in patients with heart failure. A total of 5,050 patients were enrolled in the study, including 1,132 Asian patients. Study results showed that at a median of 10.8 months of follow-up, the risk of death from cardiovascular disease or first hospitalization due to heart failure was about 10% lower in the Verquvo group than that of the placebo group, and the trial met its primary efficacy endpoint with an annual absolute risk reduction of 4.2%. Kerendia, the first kidney failure drug introduced in 20 years Kerendia was approved in Korea in May 2022 by the KFDA for the treatment of adult patients with chronic kidney disease (CKD) and Type 2 diabetes to reduce the risk of end-stage kidney disease (ESKD) and a sustained decline in estimated glomerular filtration rate (eGFR), and cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure. Until now, only treatments that target hemodynamic changes and metabolic abnormalities, 2 of the 3 causes that worsen chronic kidney disease in type 2 diabetes, had existed, but the introduction of Kerendia made available a treatment that inhibits inflammation and fibrosis in the kidneys. Kerendia’s reimbursement approval was based on the reduction in kidney disease progression, cardiovascular benefit, and safety that was demonstrated through the Phase III trials FIDELIO-DKD and FIGARO-DKD. In the FIDELIO-DKD study, Kerendia significantly reduced the incidence of a sustained decline in eGFR of ≥ 40%, kidney failure (defined as chronic dialysis, kidney transplantation, or a sustained decrease in eGFR to < 15 mL/min/1.73 m2 ), or renal death by 18% compared with placebo.
- Company
- Hanmi Pharm ‘confirms the effect of SERM+Vitamin D combo’
- by Son, Hyung-Min Feb 29, 2024 06:03am
- Hanmi Pharmaceutical announced on the 27th that the results of big data-based research on 'SERM+Vitamin D combination drugs', including its own ‘RaboneD’, were published in the SCI-level international journal, 'Osteoporosis International'. RaboneD is an osteoporosis treatment developed by Hanmi Pharmaceutical that combines vitamin D with the SERM class raloxifene. The study compared the efficacy of selective estrogen receptor modulator (SERM) + vitamin D combination and SERM alone in 2,885 patients diagnosed with osteoporosis using insurance claims data from the National Health Insurance Service from 2017 to 2019. Sang-Min Kim, Professor of Orthopedic Surgery at Korea University College of Medicine Guro Hospital, Seong-Eun Byun, Professor of Orthopaedic Surgery, CHA Bundang Medical Center, and Hanmi Pharm’s data science team participated in the study. Study results showed that the SERM+Vitamin D combination significantly lowered the risk of osteoporotic fractures by approximately 23% compared with SERM alone, and the combination reduced the risk of hip fracture by approximately 75% compared with SERM alone. This is the first real-world, data-driven study to analyze the fracture reduction effect of a SERM+vitamin D combination compared with SERM alone. The results showed that the SERM+Vitamin D combination was effective in reducing the risk of hip fracture as well as osteoporotic fractures compared to SERM alone. Professor Sang-Min Kim, said, "We found that the risk of osteoporotic fracture was significantly lower in the SERM+Vitamin D administered group compared with the monotherapy group in women with osteoporosis aged 50 years and older in Korea. The results suggest that the SERM+Vitamin D combination may be a viable option for postmenopausal women with a relatively low fracture risk.” Professor Seong-Eun Byun, said, “SERM class osteoporosis treatments not only improve bone density and lipid profiles, but also act like antiestrogen in the uterus and breast, so there is less concern about the risk of endometrial and breast cancer. As Vitamin D is an important factor that controls the whole body calcium homeostasis and is known to be necessary for bone health, several guidelines recommend adequate intake of vitamin D for patients with osteoporosis." An Hanmi Pharmaceutical official said, "As a typical chronic disease, the number of osteoporotic fractures has been continuously increasing with Korea’s entry into a super-aged society. Therefore, we expect the results of this study to broaden the treatment options for doctors and patients.”
- Company
- Roche Korea appoints Ezat Azem as new CEO
- by Eo, Yun-Ho Feb 29, 2024 06:03am
- Roche Korea is welcoming its new CEO, who will take up the position after a two-month vacancy. According to an interview, Roche Korea recently appointed Ezat Azem as new CEO. Before his appointment in Korea, Ezat Azem was a General Manager in Roche’s Greece subsidiary. Ezat Azem joined Roche’s Israel subsidiary in 1997 and worked in the marketing business unit. Later, he headed the subsidiaries in Slovenia and Greece. Ezat Azem has a background in medical training, having graduated from The Hebrew University of Jerusalem Medical School. Later, he completed an executive MBA from Tel Aviv University. Meanwhile, former Roche Korea CEO Nic Horridge retired in 2023 and has been appointed head of the Australian subsidiary. Nic Horridge was appointed as the head of Roche Korea in October 2018 and led the corporation for approximately five years. While he was in office, Nic Horridge’s significant achievements included the expansion of the anticancer immunotherapy ‘Tecentriq (atezolizumab)’ to include first-line treatment of lung cancer. Additionally, he facilitated new listings of ‘Evrysdi (risdiplam)‘ for spinal muscular atrophy, ‘Vabysmo (faricimab)’ for eye diseases, and ‘Rozlytrek (entrectinib),’ a tumor-agnostic drug.
- Company
- K-Bio’s potential rises in targeted anticancer therapy
- by Son, Hyung-Min Feb 29, 2024 06:03am
- The achievements made by the pharmaceutical and bio-industry companies in Korea in developing targeted antitumor therapies are being introduced at academic conferences overseas. iLeadBMS and PharosiBio have announced positive preclinical study results, and have received the green light to enter main clinical trials. The ESMO Targeted Anticancer Therapies Congress 2024 was held in Paris, France, for 3 days from February 26. The European Society for Medical Oncology, one of the world's three major oncology societies, organizes the congress every year to showcase promising new targets and candidates. On the 26th, iLeadBMS, a drug developer subsidiary of Ildong Pharmaceutical, presented clinical trial results on its IL2106, a molecular glue (targeted protein degradation, TPD), through a poster presentation. Founded in December 2020, iLeadBMS is a bioventure that develops new drugs in the field of small molecules. Ildong Pharmaceutical became the company’s largest shareholder in July 2021. The TPD molecule being developed by iLeadBMS has a mechanism of action that degrades proteins that cause cancer and eliminates the target itself. Targeted anticancer drugs inhibit tumor growth by acting on the target protein, but TPDs offer an advantage as they target the cause of the disease. Although no TPD product has been commercialized yet, pharmaceutical companies that have seen the promise of the technology have been continuously joining in on the challenge. In addition to Ildong Pharmaceutical, Novo Nordisk and Daewoong Pharmaceutical have entered the development stage. iLeadBMS targets CDK12, a protein that regulates the expression of genes related to cancer. The CDK12 protein is known to be expressed in several solid tumors, including breast and gastric cancers. In a preclinical trial, IL2106 potently inhibited cells expressing triple-negative breast cancer and HER2-negative gastric cancer through targeted protein degradation. IL6-110 was particularly successful in significantly reducing cyclin K levels in HCC70 cells that cause triple-negative breast cancer. In a study conducted on mouse models, IL2106 demonstrated a favorable pharmacodynamic (PK) profile using a single oral dose. The team concluded, "These findings can serve as evidence that molecular glues could serve as a novel CDK12/13 inhibitor.” On the 26th, PharosiBio also announced through a poster presentation that it had confirmed the efficacy of its colorectal cancer drug candidate, PHI-501, in a preclinical trial. PHI-501 is a bispecific antibody that targets pan-RAF and DDR1 (Discoidin Domain Receptor 1). By targeting the two biomarkers, PharosiBio expects its candidate to show efficacy in inhibiting cancer cell growth and metastasis. The preclinical trial was conducted on the mouse in vivo model to confirm PHI-501’s mechanism of action as monotherapy, on whether it can overcome resistance to BRAF inhibitors while showing antitumor effects. Results showed that PHI-501 suppressed tumor growth in a colon cancer xenograft model with BRAF or KRAS mutations. More specifically, PHI-501 showed 96% tumor suppression in the BRAF xenograft model and 83.3% tumor suppression in the KRAS xenograft model. PHI-501 also suppressed tumor growth by 76.1% in a model that showed resistance to the recently approved colorectal cancer drug Vitrakvi by Ono Pharmaceutical. Based on the positive results found in preclinical trial results, PharosiBio plans to initiate clinical trials to confirm the efficacy of PHI-501.
- Company
- Saxenda and Qsymia take up 57% of the obesity market share
- by Chon, Seung-Hyun Feb 28, 2024 10:35am
- Last year, Korea’s obesity drug market size reached its largest size in history. It broke the record in 2019, and since then, the market size expanded for five consecutive years. Saxenda and Qsymia account for 60 % of the total market share. Meanwhile, sales of previous obesity drugs, such as psychotropic drugs, are declining, further polarizing the market. As blockbuster drugs gaining popularity overseas are nearing launch in Korea, the dynamics of the Korean obesity drug market are expected to change in the future. The market for obesity drugs was 178 billion won last year, up 1.3% from the previous year, according to a pharmaceutical market research company IQVIA on the 29th. The market for obesity drugs reached 134.1 billion won in 2019, hitting a new record in ten years, and changed its record for four consecutive years. The market has been growing rapidly every year, with an increase of 83.9% over five years since it made 96.8 billion won in 2018. Annual obesity market size (left) and market share percentages of Saxenda and Qsymia in Korea (right) (Unit: 100 million won, Source: IQVIA). The introduction of Saxenda and Qsymia recently has expanded the market for obesity drugs. Last year, Saxenda recorded sales of 66.8 billion won, marking a 13.4% increase compared to the previous year, achieving a new record for two consecutive years. After recording sales of 42.6 billion won in 2019, Saxenda slowed in sales in 2020 and 2021, with 36.8 billion won and 36.2 billion won, respectively. It is analyzed that due to limited outdoor activities during the initial spread of Covid-19, the interest in obesity drugs may have decreased. However, it has been noted that the demand for Saxenda rose as many people gained weight due to reduced outdoor activities during the Covid-19 pandemic since 2020, and as outdoor activities resumed, the demand for Saxenda continued to increase. In comparison to the sales in 2020, Saxenda's sales in 2022 increased by 84.4% over the course of two years. Saxenda, launched in Korea in 2018, is the first glucagon-like peptide-1 (GLP-1) agonist medication for obesity. It contains the same ingredient as Victoza (ingredient: liraglutide), which is prescribed to patients with type 2 diabetes, but with different methods of administration and dosages. Saxenda became the top-selling drug in the market after recording sales of 42.6 billion won in 2019, just after its launch, and maintained the place for five consecutive years. The mechanism of action of Saxenda was designed similarly to the body’s GLP-1, leading to the suppression of appetite and weight loss. It gained popularity with the perception that it is relatively safer than existing weight-loss drugs. According to estimates, Saxenda took up a 37.5% market share of the obesity market last year. While Saxenda’s market share grew significantly from 7.8% in 2018 to 31.8% in 2019, it slowed down in 2020 and 2021, holding 25.8% and 25.2%, respectively. However, in 2022, Saxenda’s market share increased to over 30% and continued to grow last year. Alvogen Korea’s Qsymia has been gaining popularity recently. Qsymia reached sales of 35.5 billion won last year, an increase of 18.0 % compared to the previous year. In two years since 2021, when it made 26.2 billion won, the sales expanded by 35.4%. Qsymia, a combination drug of “phentermine’ and ‘topiramate,’ was launched in late 2019. Alvogen Korea acquired the sales rights for Qsymia in Korea from Vivus of the United States in 2017. Alvogen initiated domestic marketing through a joint sales agreement with Chong Kun Dang. Despite oral administration, Qsymia has a relatively small amount of psychotropic drug ingredients, and it has the advantage that it can be prescribed for an extended period. Alvogen Korea's extensive sales networks in the domestic obesity market, gained from its previous experience selling Furing and Furimin, synergized with Chong Kun Dang's business power to penetrate the market with Qsymia rapidly. Last year, Qsymia's market share in the obesity treatment market increased by 2.8% compared to the previous year, reaching 19.9%. The combined market share of Saxenda and Qsymia accounted for 57.5% of the total obesity market last year. The market share of Saxenda and Qsymia increased by 16.0% over two years, from 41.5% in 2020, significantly enhancing their market influence. In contrast, existing obesity drugs, excluding Saxenda and Qsymia, showed weakness overall. Sales of obesity drugs, excluding Saxenda and Qsymia, decreased by 12.7% to 757 billion won compared to the previous year. Daewoong Pharmaceutical's Dietamin saw a decrease in sales to 7 billion won last year, down 11.5% from the previous year. Huons' Hutermin recorded sales of 4.3 billion won, a 10.7% decrease from the prior year. The market share of existing obesity treatments, excluding Saxenda and Qsymia, was 68.2% in 2019 but decreased to 42.5% last year. The industry anticipates that the emergence of overseas validated blockbuster treatments for obesity would bring significant changes in market dynamics. Last April, the Ministry of Food and Drug Safety (MFDS) approved Novo Nordisk's Wegovy. Wegovy is a GLP-1 agonist in the same class as Saxenda. Novo Nordisk improved upon Saxenda, administered once daily, by making Wegovy a once-weekly injection. Since its release in the U.S. market, Wegovy's demand has surged to the point of shortages, with even Ozempic, a diabetes treatment with the same ingredient and usage, experiencing stockouts due to its high popularity. Eli Lilly's Mounjaro received approval from the MFDS in June last year. Mounjaro is a next-generation GLP-1 agonist that activates GLP-1 and GIP receptors with a once-weekly dose. It was approved as a treatment for type 2 diabetes and is expected to secure indications for obesity treatment in the future. Since its approval in the United States last year, Mounjaro generated sales of 2 trillion won in the first half of this year. With Mounjaro's approval as an obesity treatment, it is expected to bring significant changes in the obesity drug market alongside Wegovy.
- Company
- KRPIA appoints Sanofi CEO Kay Bae as new chair
- by Feb 28, 2024 05:50am
- Kay Bae (Bae Kyung-eun) appointed as the new chair of KRPIA The Korean Research-based Pharmaceutical Industry Association (KRPIA) announced on the 23rd that it has appointed Kay Bae (Bae Kyung-eun), Country Lead of Sanofi-Aventis Korea, as the 15th chair of KRPIA. Bae served on the KRPIA board of directors in September 2013, and she has been a member of the vice-chair body, contributing to the growth of KRPIA. Bae graduated from the College of Pharmacy at Seoul National University and received a master’s degree in global management from Aalto University School of Business. Bae gained diverse experiences in the field, including positions as Global Head of Business Units, Head of Anticancer Drugs and Prescription Medicines, and CEO at global pharmaceutical companies since 1994. For over ten years, Bae served as the head of Sanofi-Aventis Korea, where she is currently the CEO. She led the unification of independent business units, Sanofi Pasteur, a subsidiary dedicated to producing vaccines, and Sanofi Genzyme, a part of the Specialty Care franchise, into a single brand. Before becoming CEO of Sanfofi-Aventis Korea and Genzyme Korea, Bae worked at Novartis Korea and Novartis Unites States. Since September 2022, Bae has been serving as the chairperson of the Healthcare Committee at the European Chamber of Commerce in Korea (ECCK). Bae is known for having a profound understanding of the pharmaceutical industry and the Korean systems and policies while demonstrating strong leadership skills. “We will strive to provide rapid and broadened treatment benefits of innovative new drugs to patients in Korea amid the rapidly evolving healthcare and medical industry,” Bae said. “To promote innovative development in the domestic pharmaceutical and biotechnology industry, we plan to collaborate with other domestic companies by strengthening our open innovation platform,” Bae added. The KRPIA has announced the appointment of new vice-chairs along with a new chairperson. KRPIA’s vice-chairs are △Jae (Byungjae) Yoo of Novartis Korea, △Hye Young Lee of BMS Pharmaceutical Korea, and △Dong-Wook Oh of Pfizer Korea. A new board of directors was elected through a voting process in mid-January last year: △Maurizio Borgatta of GSK Korea △Jaeyeon Choi of Gilead Sciences Korea, △Christoph Hamann of Merck Korea, △Ji-young Sohn of Moderna Korea, △JinA Lee of Bayer Korea, △Sang Kyung Noh of Amgen Korea, △Junil Kim of Astellas Pharma Korea, △Soyoung Kang of AbbVie Korea, and △Albert Kim of MSD Korea.
- Company
- Immuno-oncology market triples in 4 years
- by Son, Hyung-Min Feb 28, 2024 05:50am
- Sales in the immuno-oncology market surpassed KRW 700 billion last year, driven by the surge in sales of Keytruda and Opdivo. The market has more than tripled in size over the past 4 years. Keytruda and Opdivo together accounted for 72.4% of the market and generated more than KRW 500 billion in sales. The market’s prospects are also bright with major immuno-oncology drugs showing additional efficacy in various solid tumors. According to the market research institution IQVIA on the 27th, the total immuno-oncology treatment market has recorded KRW 730.8 billion in the past year, a 46.6% increase from the KRW 498.3 billion in the previous year. Sales have been growing steeply in the immuno-oncology market. The market, which was worth KRW 200 billion in 2019, reached KRW 700 billion last year after recording KRW 407 billion in 2021 and KRW 498.3 billion in 2022. Immuno-Oncology Drug Market Size (Unit: KRW 100 million) Immuno-oncology drugs target PD-1/PD-L1 biomarkers that are expressed in major solid tumors. This is why the drugs have expanded their indications to several solid tumors, and sales are surging. In addition to their better effect, immuno-oncology drugs are also known to have fewer side effects than first-generation cytotoxic anti-cancer drugs and second-generation targeted anticancer drugs. Since the immuno-oncology drugs work by strengthening the body's immune system, side effects such as hair loss, vomiting, nausea, diarrhea, and bone marrow suppression are relatively mild. Keytruda, which owns 26 indications, approaches KRW 400 billion in sales...Opdivo’s sales surpass the KRW 100 billion mark #EB The market leader is MSD's Keytruda. Keytruda generated KRW 398.7 billion in sales last year, up 66.4% YoY. It occupied 54.6% of the market. Keytruda is approved for 26 approved indications in Korea, owning the most amount of indications among all cancer drugs. However, only 4 of the cancers are reimbursable: lung cancer, Hodgkin's lymphoma, urothelial carcinoma, and melanoma. MSD is seeking reimbursement for a variety of other solid tumors, including triple-negative breast and head and neck cancer. Keytruda's sales may surge further if its reimbursement is further extended. In second place was Opdivo. Opdivo generated KRW 130.4 billion in sales last year, up 18.7% from KRW 109.8 billion in 2022. After hovering in the KRW 60 billion range from 2019 to 2020, the company surpassed the KRW 100 billion mark in 2022 after reaching KRW 85 billion in 2019. Together, Keytruda and Opdivo generated KRW 529.1 billion in sales last year, accounting for 72.4% of the market. Opdivo is a PD-1 class immuno-oncology drug co-developed by BMS and Japan's Ono Pharmaceutical. It has 22 approved indications in Korea, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Both companies have been steadily expanding the number of their solid tumor indication since their approval. In addition to extending Opdivo’s reimbursement coverage, BMS and Ono plan to develop a subcutaneous (SC) formulation to expand options for the patients. Opdivo's major patents are set to expire in 2028. BMS confirmed that Opdivo’s subcutaneous (SC) formulation was non-inferior to the intravenous (IV) formulation in a Phase III clinical trial conducted to confirm the efficacy of the SC formulation. The safety results were also comparable in both arms. The SC formulation can be administered in less than 5 minutes, compared to the 1 hour required for the existing IV formulation. BMS is preparing to apply for approval of its SC formulation with regulatory authorities around the world. Tecentriq and Imfinzi gains ground in intractable cancers Roche's Tecentriq and AstraZeneca's Imfinzi also showed marked sales growth. Roche Tecentriq generated KRW 97.3 billion in sales last year, up 18.9% YoY. After posting KRW 37 billion in 2020 and doubling its sales in 2021, Tecentriq’s sales have been on a steady rise. Roche has been rapidly expanding Tecentriq’s indication by actively accepting the government’s requests. Tysentriq gained coverage for lung cancer within a year of approval and expanded coverage in 2019 by removing the PD-L1 expression limit. Roche plans to expand Tecentriq’s indications through combined use with targeted cancer drugs. Tecentriq, in combination with Avastin, became the first immuno-oncology drug to be reimbursed for the first-line treatment of liver cancer. Roche is also conducting combination trials with NT-I7, an anti-interleukin (IL)-7 inhibitor developed by a Korean biotech NeoImmuneTech, in lung and skin cancers. AstraZeneca's Imfinzi posted sales of KRW 82.7 billion last year, up 57.8% from KRW 52.4 billion in 2022. After generating KRW 3.4 billion in sales in 2019, Imfinzi’s sales surged 624% to KRW 24.6 billion the following year. With sales exceeding KRW 80 billion last year, Imfinzi ranked fourth in the immuno-oncology market. Imfinzi’s strength is that it is the first immuno-oncology drug to show efficacy in biliary tract cancer. In 2022, AstraZeneca received approval for the Imfinzi+gemcitabine+cisplatin combination in Korea. This approval established the Imfinzi combination as the new standard of care in biliary tract cancer for 12 years. AstraZeneca is currently in the process of extending Imfinzi’s reimbursement to its biliary tract cancer indication. BMS plans to extend indications for the Yervoy+Opdivo combo...Bavencio’s sales increase with reimbursement in urothelial cancer BMS On the other hand, Yerovy’s sales growth was not as dramatic. Sales of Yervoy, which is the only immuno-oncology drug to target CTLA-4, grew only 12.6% last year, generating sales of KRW 16 billion. In 2021, Yervoy received approval for use in combination with Opdivo in 2021. However, the maximum dosing interval was set at 2 years, meaning that even if it works, patients will not be eligible for additional reimbursement afterward. BMS plans to explore multiple uses for the Yervoy and Opdivo combination. The company is currently exploring the combination of metastatic colorectal cancer, squamous cell carcinoma, and head and neck cancer. Merck's Bavencio generated KRW 5.7 billion in sales last year. Sales of Bavencio grew with its reimbursement approval in metastatic urothelial cancer. Bavencio, which was approved in Korea in 2019, secured reimbursement as a first-line maintenance therapy for urothelial cancer in 2023. The variable is Padcev. Padcev, which is an antibody-drug conjugate (ADC) cancer drug developed by Astellas and Seegen, has confirmed efficacy results as a first-line treatment in urothelial cancer. Based on the results of the study, the company is accelerating its efforts to receive approval as a first-line treatment in urothelial cancer This could have implications for Bavencio, as it is being used as a maintenance therapy in the first-line setting.
- Company
- Will the first oHCM drug Camzyos be reimbursed in Korea?
- by Eo, Yun-Ho Feb 28, 2024 05:50am
- The industry’s eyes are focused on the reimbursement review progress of Camzyos, the first treatment for obstructive hypertrophic cardiomyopathy. Dailypharm’s coverage found that the pharmacoeconomic evaluations for Camzyos(mavacamten), BMS Pharmaceutical Korea's new drug for obstructive hypertrophic cardiomyopathy (oHCM), is now complete and that it will be submitted for review by the Health Insurance Review and Assessment Service's Pharmacoeconomic Evaluation Subcommittee next month (March). Being the first treatment option in its field, many challenges are expected in its reimbursement approval process. However, as the government has shown a willingness to improve the valuation process for new drugs, including providing preferential treatment for innovative new drugs, it remains to be seen whether this will positively impact Camzyos’s reimbursement process. Camzyos is the first and only cardiac myosin inhibitor that specifically targets excess cross-bridge formation of myosin and actin proteins, the main cause of oHCM. It improves left ventricular hypertrophy and left ventricular outflow tract obstruction by separating myosin from actin, relaxing the overcontracted heart muscle. Due to the lack of a cure, oHC has long been managed with off-label drug use. The European Society of Cardiology (ESC) revised its HCM guidelines for the first time in 9 years with the introduction of Camzyos. Before then, HCM guidelines have been based on small observational data reported from individual institutions, retrospective analyses, or expert consensus opinions. Therefore, Camzyos was a game-changer in the field. After demonstrating its significant effect in two large-scale Phase III randomized controlled trials (RCTs), Camzyos was recommended at the highest evidence level, A, for the first time among treatment options in the ESC guidelines. The American College of Cardiology (ACC) and American Heart Association (AHA) are also currently preparing to update their guidelines. Based on the Phase III trial data, Camzyos received a breakthrough therapy designation (BTD) and was approved by the US FDA. Based on these factors, Camzyos appears to meet the criteria for an innovative new drug announced by the government last year, where: ▲ there is no substitute or therapeutically equivalent product or treatment; ▲ has shown clinically meaningful improvement, such as a significant prolongation of survival period; ▲has received the Ministry of Food and Drug Safety’s GIFT (Global Innovative products on Fast Track) designation, US FDA’s Breakthrough Therapy Designation (BTD), and was approved through the European EMA’s Priority Medicines scheme (PRIME). With reimbursement for the breast cancer drug Enhertu (trastuzumab deruxtecan) recently making progress by passing an unusual ICER threshold, attention is focused on whether Camzyos can follow suit. In the Phase III EXPLORER-HCM trial, which served as the basis for Camzyos’s approval, Camzyos achieved and improved the primary composite endpoint of the proportion of patients with decreased symptom burden (by NYHA class) and functional capacity (peak oxygen consumption, pVO2) by more than 2 times compared with placebo. In particular, 20% of the patients who received treatment with Camzyos achieved both primary endpoints, pVO2 improvement, and the NYHA class requirement. Also, the dynamic left ventricular outflow tract obstruction was reduced by over 4 times with the use of Camzyos. 7 out of 10 patients treated with Camzyos improved to the extent that they would not consider surgery, and showed consistent benefits over 30 weeks.
